Our study showed polymorphisms in MHC genes that were associated with survival outcomes in bevacizumab-treated CRC patients in FIRE-3, TRIBE, and MAVERICC trials, and implicated future studies that could decipher the association between MHC variants and the VEGF-A pathway. This evidence concerns the gene VEGFA and colorectal carcinoma.